This week’s insights come directly from our senior equity analyst Malik Ahmed Khan.

IPO range sits well below the September target

Anthropic set an IPO range of $70-$78 per share, valuing the business at up to $1.4 trillion on a fully diluted basis. That is well below the $2 trillion considered in September. There are media reports the range may shift.

We think the lower range reflects weaker sentiment towards artificial intelligence. Investors grown wary of the AI trade, with concerns about data centre construction and slowing AI spending. Those concerns are particularly relevant to Anthropic, given its commitments of more than US$900 billion for computing capacity.

COTW: Anthropic FV estimate

Source: Morningstar. Data as of Nov. 11, 2026

Our $92 fair value implies 24% upside to the range midpoint

We value narrow-moat Anthropic at US $92 per share, or US$1.7 trillion in equity value. Against the USD 74 midpoint of the range, that implies 24% upside. Our valuation rests on a five-year revenue growth of 47% from 2027 to2031.

COTW: Anthropic revenue growth estimate

We see three drivers. First, higher spending from existing customers, with almost 12,000 already spending more than USD 100,000 a year. Second, new customers: more than half of the Fortune 500 are already active customers, leaving nearly half spending little or nothing. Third, distribution through AWS and Google Cloud, which lets Anthropic grow without adding sales staff at the same pace.

The range of outcomes is wide

The gap between our scenarios is large. Our bull case assumes rapid adoption of Anthropic’s Claude AI and market share gains against rivals such as OpenAI. That gives a fair value of US$188 a share. That is more than twice our base case and more than 150% above the midpoint. Our bear case assumes slower business adoption and stronger competition from rivals that release their AI models openly. That gives US$25 a share, or 66% below the midpoint

COTW: Anthropic's Compute Efficiency

Anthropic’s IPO documents say its AI already helps develop its future models. If this accelerates progress, our base-case valuation could prove too conservative. If safety problems emerge, an industry pause or tougher regulation could slow growth. Investors must assess whether the price adequately reflects both the growth opportunity and these risks.